chr3-10149906-C-T

Variant summary

Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PVS1PM2_SupportingPS4_Moderate

This summary comes from the ClinGen Evidence Repository: The NM_000551.3(VHL):c.583C>T (p.Gln195Ter) variant in VHL is a truncating mutation that terminates the VHL protein at position 195, which resides in the second Beta domain (PVS1). A total of 13 probands or families have been identified with this variant, and they have clinical features of VHL (some Type 1, some Type 2A). 11 probands or families were identified in the following PMIDs: 20660572, 8707293, 23298237, 21463266, 9408111, 17661816, 25867206, 17024664. CIViC EIDs (https://civicdb.org) are: 5472, 5360, 5691, 8693, 9255, 5097, 6623, 5134. Two additional affected cases were contributed by a commercial laboratory, with VHL phenotypes and one case has segregation data. The case total of 13 equates to moderate evidence (PS4_Moderate). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal-dominant von Hippel-Lindau disease (VHL disease) based on the ACMG/AMP criteria applied, as specified by the ClinGen VHL VCEP Version 1.0 (Specifications approval date: 02/26/2024. Variant Approval Date 06/25/2024). LINK:https://erepo.genome.network/evrepo/ui/classification/CA70052558/MONDO:0008667/078

Frequency

Genomes: not found (cov: 32)

Consequence

VHL
NM_000551.4 stop_gained

Scores

2
2
3

Clinical Significance

Pathogenic reviewed by expert panel P:4

Conservation

PhyloP100: -0.273

Publications

14 publications found
Variant links:
Genes affected
VHL (HGNC:12687): (von Hippel-Lindau tumor suppressor) This gene encodes a component of a ubiquitination complex. The encoded protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. In addition to oxygen-related gene expression, this protein plays a role in many other cellular processes including cilia formation, cytokine signaling, regulation of senescence, and formation of the extracellular matrix. Variants of this gene are associated with von Hippel-Lindau syndrome, pheochromocytoma, erythrocytosis, renal cell carcinoma, and cerebellar hemangioblastoma. [provided by RefSeq, Jun 2022]
VHL Gene-Disease associations (from GenCC):
  • pheochromocytoma
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • von Hippel-Lindau disease
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P, Orphanet
  • renal cell carcinoma
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • autosomal recessive secondary polycythemia not associated with VHL gene
    Inheritance: AR Classification: STRONG Submitted by: Ambry Genetics
  • Chuvash polycythemia
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet
  • hereditary pheochromocytoma-paraganglioma
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 11 ACMG points.

PVS1
For more information check the summary or visit ClinGen Evidence Repository.
PS4
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
VHLNM_000551.4 linkc.583C>T p.Gln195* stop_gained Exon 3 of 3 ENST00000256474.3 NP_000542.1 P40337-1A0A024R2F2
VHLNM_198156.3 linkc.460C>T p.Gln154* stop_gained Exon 2 of 2 NP_937799.1 P40337-2A0A0S2Z4K1
VHLNR_176335.1 linkn.912C>T non_coding_transcript_exon_variant Exon 4 of 4
VHLNM_001354723.2 linkc.*137C>T 3_prime_UTR_variant Exon 3 of 3 NP_001341652.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
VHLENST00000256474.3 linkc.583C>T p.Gln195* stop_gained Exon 3 of 3 1 NM_000551.4 ENSP00000256474.3 P40337-1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
30
GnomAD4 genome
Cov.:
32
Alfa
AF:
0.00
Hom.:
0

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Von Hippel-Lindau syndrome Pathogenic:3
Jun 06, 2023
Laboratory of Molecular and Cytogenetics, Department of Anatomy, All India Institute of Medical Sciences (AIIMS)
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
CIViC knowledgebase, Washington University School of Medicine
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:curation

VHL nonsense variant Q195* (c.583C>T) is pathogenic for Von Hippel Landau Disease. VHL variant Q195* (c.583C>T) introduces an early stop codon resulting in a truncated protein. Loss of function VHL variants have been implicated with pathogenicity for Von Hippel Landau disease (PVS1), and this variant has been observed in patients with symptoms and family history highly characteristic of Von Hippel Landau disease (PP4). The variant does not appear in the gnomAD population database (PM2). -

Jun 25, 2024
ClinGen VHL Variant Curation Expert Panel, ClinGen
Significance:Pathogenic
Review Status:reviewed by expert panel
Collection Method:curation

The NM_000551.3(VHL):c.583C>T (p.Gln195Ter) variant in VHL is a truncating mutation that terminates the VHL protein at position 195, which resides in the second Beta domain (PVS1). A total of 13 probands or families have been identified with this variant, and they have clinical features of VHL (some Type 1, some Type 2A). 11 probands or families were identified in the following PMIDs: 20660572, 8707293, 23298237, 21463266, 9408111, 17661816, 25867206, 17024664. CIViC EIDs (https://civicdb.org) are: 5472, 5360, 5691, 8693, 9255, 5097, 6623, 5134. Two additional affected cases were contributed by a commercial laboratory, with VHL phenotypes and one case has segregation data. The case total of 13 equates to moderate evidence (PS4_Moderate). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal-dominant von Hippel-Lindau disease (VHL disease) based on the ACMG/AMP criteria applied, as specified by the ClinGen VHL VCEP Version 1.0 (Specifications approval date: 02/26/2024. Variant Approval Date 06/25/2024). -

Hereditary cancer-predisposing syndrome Pathogenic:1
Apr 08, 2025
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Q195* pathogenic mutation (also known as c.583C>T), located in coding exon 3 of the VHL gene, results from a C to T substitution at nucleotide position 583. This alteration occurs at the 3' terminus of theVHL gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 19 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). This pathogenic mutation has been reported in numerous families diagnosed with von Hippel-Lindau (VHL) syndrome (Crossey PA et al. Hum Mol Genet. 1994 Aug;3(8):1303-8; Hes FJ et al. Clin Genet. 2007 Aug;72(2):122-9; Losonczy G et al. BMC Med Genet. 2013 Jan 8;14:3). This mutation has also been reported in one individual diagnosed with a nonsyndromic pheochromocytoma (Neumann HP et al. N Engl J Med. 2002 May 9;346(19):1459-66). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Note that this alteration is also referred to as c.796C>T in published literature. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.62
D
BayesDel_noAF
Pathogenic
0.27
CADD
Pathogenic
35
DANN
Uncertain
0.98
Eigen
Uncertain
0.21
Eigen_PC
Benign
-0.090
FATHMM_MKL
Benign
0.063
N
PhyloP100
-0.27
Vest4
0.72
GERP RS
0.47
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=9/191
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs5030825; hg19: chr3-10191590; COSMIC: COSV56548498; API